Processing

Please wait...

Settings

Settings

Goto Application

1. WO2012059594 - MINERALCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CORTICOID-INDUCED OBESITY

Publication Number WO/2012/059594
Publication Date 10.05.2012
International Application No. PCT/EP2011/069464
International Filing Date 04.11.2011
IPC
A61K 31/585 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
58containing heterocyclic rings, e.g. aldosterone, danazol, stanozolol, pancuronium, digitogenin
585containing lactone rings, e.g. oxandrolone, bufalin
A61P 5/42 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
5Drugs for disorders of the endocrine system
38of the suprarenal hormones
42for decreasing, blocking or antagonising the activity of mineralocorticosteroids
A61P 5/46 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
5Drugs for disorders of the endocrine system
38of the suprarenal hormones
46for decreasing, blocking or antagonising the activity of glucocorticosteroids
CPC
A61K 31/585
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
58containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
585containing lactone rings, e.g. oxandrolone, bufalin
A61P 5/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
5Drugs for disorders of the endocrine system
38of the suprarenal hormones
42for decreasing, blocking or antagonising the activity of mineralocorticosteroids
A61P 5/46
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
5Drugs for disorders of the endocrine system
38of the suprarenal hormones
46for decreasing, blocking or antagonising the activity of glucocorticosteroids
Applicants
  • BAYER INTELLECTUAL PROPERTY GMBH (AllExceptUS)
  • PATCHEV, Vladimir [DE]/[DE] (UsOnly)
  • BORDEN, Steffen [DE]/[DE] (UsOnly)
  • CAPRIO, Massimiliano [IT]/[IT] (UsOnly)
  • ROSANO, Giuseppe [IT]/[GB] (UsOnly)
  • FABBRI, Andrea [IT]/[IT] (UsOnly)
  • BOHLMANN, Rolf [DE]/[DE] (UsOnly)
Inventors
  • PATCHEV, Vladimir
  • BORDEN, Steffen
  • CAPRIO, Massimiliano
  • ROSANO, Giuseppe
  • FABBRI, Andrea
  • BOHLMANN, Rolf
Agents
  • PLOUGMANN & VINGTOFT A/S
Priority Data
10190061.104.11.2010EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) MINERALCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CORTICOID-INDUCED OBESITY
(FR) ANTAGONISTES DE RÉCEPTEUR DE MINÉRALOCORTICOÏDE POUR LE TRAITEMENT DE L'OBÉSITÉ INDUITE PAR CORTICOÏDE
Abstract
(EN)
The present invention is on the field of prevention and/or treatment of adipogenesis and obesity. According to the invention mineralcorticoid receptor antagonists are used as the therapeutically active principle. The mineralcorticoid receptor antagonists used in this invention are capable of displacing the endogenous glucocorticoid cortisol from the antimineralcorticoid receptor.
(FR)
La présente invention concerne le domaine de la prévention et/ou du traitement de l'adipogenèse et de l'obésité. Selon l'invention, des antagonistes de récepteur de minéralocorticoïde sont utilisés en tant que substance thérapeutiquement active. Les antagonistes de récepteur de minéralocorticoïde utilisés dans cette invention sont capables de déplacer le glucocorticoïde cortisol endogène du récepteur antiminéralocorticoïde.
Latest bibliographic data on file with the International Bureau